SECsense Logo

AstraZeneca PLC 6-K Report: Key Insights on ADS Acquisition by Director Karen Knudsen

$AZN
Form 6-K
Filed on: 2025-09-25
Source
AstraZeneca PLC 6-K Report: Key Insights on ADS Acquisition by Director Karen Knudsen

Here are the key insights and information extracted from the financial report section provided:

  1. Company Information:
  • Name: AstraZeneca PLC
  • Address: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
  1. Filing Information:
  • Form Type: 6-K
  • Commission File Number: 001-11960
  • Filing Date: 25 September 2025
  • Reporting Period: For the month of September 2025.
  1. Transaction Details:
  • Person Involved: Karen Knudsen, Non-Executive Director.
  • Transaction Date: 9 September 2025.
  • Nature of Transaction: Acquisition of 9 American Depositary Shares (ADSs) through the reinvestment of the first interim dividend for the year ending 31 December 2025, paid on 8 September 2025.
  • Equivalent Shares: 9 ADSs are equivalent to 4.5 ordinary shares (since two ADSs equal one ordinary share).
  • Price of Transaction: $81.0499 per ADS.
  • Volume of Transaction: 9.0737 ADSs acquired.
  1. Regulatory Compliance:
  • The notification was made in accordance with the EU Market Abuse Regulation, applicable as part of UK law.
  1. Additional Information:
  • The report confirms that AstraZeneca PLC is filing annual reports under Form 20-F.
  • The report does not indicate that the issuer is submitting this form in paper format.
  • The report mentions that the details of the issuer include its LEI (Legal Entity Identifier): PY6ZZQWO2IZFZC3IOL08.

This summary highlights the critical aspects of the transaction and the regulatory context in which it was reported.